PRESCRIPTION DRUGS PHARMA PRICES
Novartis offers payment plan for high-cost heart medicine
Novartis introduces a financing scheme with Pine Labs for its cholesterol-lowering drug, Sybrava (inclisiran), in India, aiming to broaden access by offering zero-interest EMI options. This strategy addresses the drug's high cost, previously ₹1.2 lakh per injection, and involves partnerships with Mankind Pharma, JB Pharma, and Lupin to expand market reach.
Aurobindo Pharma shares jump 2% even as Q4 profit dips marginally to Rs 903 cr
Aurobindo Pharma shares: Aurobindo Pharma reported a marginal 0.4% YoY dip in Q4FY25 PAT to Rs 903 crore, even as revenue rose 10.6% to Rs 8,382 crore. For FY25, PAT rose 10% to Rs 3,484 crore. The company highlighted strong volume-led growth, record sales, and robust performance in its European operations.
Aurobindo Pharma Q4 net dips marginally to Rs 903 cr; revenue at Rs 8,382 cr
Aurobindo Pharma on Monday reported a marginal dip in its consolidated profit after tax to Rs 903 crore for the fourth quarter ended March 2025. The Hyderabad-based drug maker posted a profit after tax (PAT) of Rs 907 crore in the January-March quarter of FY24.
MNC pharma companies: Time to take a re-look? 8 pharma stocks, 5 with an upside of up to 34%
Some time back an MNC pharma firm announced the divestment of one of its businesses in India. Another sold one of its plants. Now, with the capital in hand, they may either expand into some other segment, or farm out the extra cash as a special dividend. These companies could thus become dividend plays. If the company increases its focus on India and does it through already listed entities, then there will be strong upward re-rating. But if the focus shifts to a 100% subsidiary, there will be strong de-rating and underperformance. These stocks are thus for investors who have a high risk appetite
China’s India headache: The growing pharmaceutical industry
Indian CDMOs are strategically expanding through acquisitions in the US and Europe, driven by global pharma's nearshoring trend and a desire to diversify from China. These companies are investing in advanced technologies and specialized capabilities, particularly in biologics and complex chemistry, to capture a larger share of the global market.
Is tariff threat over? In Trump era, you have to read between the lines: 8 pharma stocks with upside potential of over 35%
President’s Trump friend got a weight-loss injection for $88 in London. The same injection costs $1,300 in the US. This led to an Executive Order telling US companies to ensure that drug prices are reduced at home. Now, if the intention is to reduce prices, tariffs cannot be imposed. That is logical. But we are living in a time when logic has little to do with what is said or done. Logic says you cannot shift the supply chain of a pharma sector just because one person so desires. Also, historically, tariffs lead to higher prices; they do not cause products to shift their production base. We can only hope that logic finally prevails.
- Go To Page 1
'Sickest generation': What RFK Jr's report says about American children and how to 'make America healthy again'
The White House has released a report, spearheaded by Health Secretary Robert F. Kennedy Jr., highlighting a public health crisis among American children. The report points to ultraprocessed foods, environmental chemicals, and overmedicalization as key drivers of chronic diseases. It calls for further research and a shift towards prevention, while downplaying traditional concerns like smoking and alcohol, sparking political pushback.
Donald Trump declares he invented a brand-new word that linguists say has been in dictionaries for over 500 years
Donald Trump said he invented the word "equalize" while announcing a drug price order, but the word has existed for centuries.
Exploring the Growth Potential of the Indian Pharmaceutical Sector
The Indian pharmaceutical sector is poised for significant growth, driven by favorable trade agreements and increasing global demand for generic medicines. This article delves into the sector's performance, outlook, and highlights key companies with promising upside potential.
Many MSME pharma firms making substandard drugs, CDSCO data shows
Data from the CDSCO reveals that numerous MSME pharmaceutical companies in India are producing substandard drugs, failing to meet safety standards. Inspections have uncovered issues with infrastructure, quality management, and manufacturing processes. A significant percentage of MSMEs have faced stop production orders due to these quality concerns, prompting calls for stricter GMP regulations.
Thailand to tighten control on cannabis after smuggling cases involving Indian & British tourists soar
Thai authorities are tightening cannabis regulations following a surge in smuggling attempts, particularly by tourists. New rules may require prescriptions for cannabis purchases. Airport inspections have increased, with many foreigners, especially British and Indian nationals, caught. Joint operations with Britain have led to significant cannabis seizures from air passengers and postal shipments.
Finally, the photos are out: Here are the things found in Diddy's room the day he was arrested and they will shock you
Sean 'Diddy' Combs faces serious charges. Images from his hotel room are now public. The images reveal drugs and cash. Investigators found ketamine and MDMA. Other items include baby oil and prescription drugs. His ex-girlfriend testified about his drug use. Prosecutors allege drug-fueled abuse. The defense claims personal use. The trial continues in Manhattan.
Mutual funds bet big on healthcare stocks after Trump’s tariff pause. Is the danger really over?
Following Trump's tariff pause in April 2025, the Nifty Healthcare index rebounded strongly, rising 7%. Mutual funds increased holdings in several healthcare stocks, with Syngene International seeing the highest buying. While some stocks like Zydus Lifesciences faced sell-offs, the sector's overall performance remained robust, outperforming the Nifty.
Piramal Pharma to stay away from prescription business in India: Nandini Piramal
Piramal Pharma is not planning to re-enter the domestic prescription formulations business, according to chairperson Nandini Piramal. Instead, the company will focus on its consumer healthcare business, potentially acquiring OTC portfolios or brands, and explore targets in its global complex hospital generics business. Piramal Pharma will continue organic expansion in its CDMO business with a capex of $100-125 million.
Obesity drug maker Novo Nordisk ousts CEO as competition weighs
Novo Nordisk CEO Lars Fruergaard Jorgensen will step down amidst growing concerns about the company's competitive position in the obesity drug market. Increased competition from Eli Lilly, particularly with Zepbound surpassing Wegovy prescriptions in the U.S., and investor disappointment with Novo Nordisk's drug pipeline have contributed to a significant share price decline.
Generic pharma companies unlikely to be impacted by Trump's order to cut Rx drug prices: Report
A report suggests Indian generic drug companies may not be affected by US President Donald Trump's order. The order aims to lower US prescription drug prices. It will match them to those of other developed nations. The 'Most-Favoured-Nation' price model will be introduced. This model will cover Medicare and Medicaid. The order may face legal challenges.
Chill, trimmed pill prices won't hurt us
Donald Trump's executive order targeting international consumer price parity for prescription drugs in the US faces implementation challenges and potential legal battles. While unlikely to significantly impact Indian generic drug exporters, the order aims to increase imports from developed economies.
US govt order unlikely to impact on Indian pharma players, says Cipla
Umang Vohra of Cipla says that the US order to lower drug costs will likely target branded drugs. He believes generic drug prices are already competitive. Vohra also states that potential US tariffs on pharmaceutical imports are not expected to significantly impact Cipla's business. He mentions that discussions between the US and Indian governments are ongoing.
Trump wants to slash prescription drug prices in US. What it means for your pharmacy bill
Donald Trump has signed a wide-reaching executive order on Monday directing drugmakers to lower the prices of their medicines to align with what other countries pay that analysts and legal experts said would be difficult to implement.The order gives drugmakers price targets in the next 30 days, and will take further action to lower prices if those companies do not make "significant progress" toward those goals. The question that remains is that how Trump's directive to pharma companies may affect your pharmacy bill.
Trump order unlikely to impact domestic generic industry working on razor-thin profits
The US order to lower prescription drug prices is unlikely to impact Indian generic drugmakers, as they already operate on low margins, experts say. The move mainly affects innovator pharma companies required to align prices with global benchmarks.
Trump’s drug price order raises alarm bells for Indian pharma
President Trump's plan to lower US prescription drug prices by aligning them with other countries could impact Indian pharmaceutical companies, which heavily rely on the US market for revenue. While primarily targeting innovator drugmakers, the move may squeeze Indian generic firms, potentially leading to margin pressure and strategic adjustments.
Pharma stocks decline amid Trump’s prescription drug price cuts announcement
The Nifty Pharma Index ended 0.2% higher Monday after tumbling almost 2.4% earlier in the day in response to Trump's remarks. The Sensex and Nifty jumped nearly 4%-posting their biggest single-day gains in four years. Of the 20 stocks in Nifty Pharma, 13 gained and seven declined.
US pharma stocks gain up to 5% on Trump's move to slash drug prices
President Trump plans to sign an executive order mandating drugmakers to align U.S. drug prices with those of other countries, setting price targets within 30 days. If companies fail to make significant progress within six months, the government will consider measures like importing drugs and export restrictions.
'We're no longer paying...': Trump sets deadline for pharma firms to lower US prescription drug costs in new order
Donald Trump signed an order to cut drug costs. Pharma companies have 30 days to comply. Otherwise, the government will limit payments. The order directs the health department to negotiate prices. US drug prices will be linked to lower costs in other countries. Trump claims this will save taxpayers trillions. He accuses other countries of exploiting America.
What is Trump's ‘most favored nation’ drug pricing policy and how will it reduce costs? Explained
President Donald Trump on Sunday announced that he will be signing an executive order to reduce prescription drug prices in the US. The 78-year-old mentioned his ‘Most Favored Nation’ (MFN) drug pricing policy, saying it will bring down prices by 30% to 80%. “I will be instituting a MOST FAVORED NATION’S POLICY whereby the United States will pay the same price as the Nation that pays the lowest price anywhere in the World," he wrote.
Trump announces 59% drug prices cut
Donald Trump plans to cut drug prices by 59 percent. He announced this after unveiling a new pharmaceutical policy. Trump aims to sign an executive order to reduce prices. The order would implement a "most favored nation's" policy. This would link US drug costs to the lowest prices paid by other countries. He tried similar plans before, but faced opposition.
Pharma stocks in focus as Trump announces cut in prescription drug prices by 59%
Trump announced that the U.S. would adopt a "Most Favored Nation" policy, under which it would pay the same price for prescription drugs as the country with the lowest rates globally. “Our Country will finally be treated fairly, and our citizens' healthcare costs will be reduced by numbers never even thought of before,” he said in a post.
Improving geopolitical cues mark a major positive for equities: Sandip Sabharwal
From a very negative environment we seem to be moving to a more constructive, positive environment in a very rapid speed. So, as things play out globally, it could have a positive impact on risky assets, mostly equities, etc, and could create some sort of corrections in gold, and other safe heaven assets.
Pie in the sky? Trump’s executive order on pharma unlikely to see the light of day: N Jayakumar
N Jayakumar of Prime Securities deems the US executive order on pharma prices as unrealistic and anticipates legal challenges. He emphasizes the dominance of large pharmacy chains and their markups on generic drugs, suggesting that inefficient distribution, rather than price control, is the core issue. Reducing distribution costs is key to making drugs more affordable for consumers.
Load More
